High-Risk Stocks: Key Trends for Agios, Navitas, Joby, and Viking
JOBY Joby Aviation Inc
$4.61 -6.87%
View chart & analysis → 
- 1The FDA is expected to respond to Agios's supplemental new drug application for sickle cell disease treatment by November 1.
- 2Navitas Semiconductor management stated that Navitas revenue will grow from less than $50 million in 2026 to a $3.5 billion Navitas serviceable addressable market (SAM) by 2030.
- 3Viking Therapeutics recently reported positive results in a maintenance therapy clinical trial.
So what's the key point?
Agios is waiting for new drug approval results, and Navitas is expected to see market growth. Viking obtained positive results in a treatment trial.
Source Nasdaq +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.